With rising costs of drug and medical device development, in addition to pressures to lower prescription and procedural costs, the Internet of Medical Things (IoMT) market has grown rapidly, increasing from $41.2 billion in 2017 to an anticipated $158.1 billion in 2022.

This is because the IoMT — which includes medical devices, wearable monitors and apps that connect to healthcare information systems — has the potential to increase clinical trial efficiency and improve our ability to support patients throughout the patient journey. As such, IoMT is set to revolutionise clinical trials, making them more efficient, effective and manageable.

In our latest whitepaper, we follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.